Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD2516 to Healthy Volunteers

A Phase I, Single-Centre, Randomised, Double-Blind, Placebo-Controlled Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2516 in Young and Elderly Healthy Volunteers After Oral Single Ascending Doses

The primary purpose of this study is to assess the safety and tolerability of AZD2516 following administration of a single dose.

Inclusion Criteria:

• Healthy white males or non-fertile females between 20 to 45 years and 65 to 80 years old.
• Weight between 50 to 100 kg and a body mass index (BMI) between 19 to 28 kg/m2

Exclusion Criteria:

• History of previous or ongoing psychiatric disease.
• Abnormalities in ECG that may interfere with interpretation of data.